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Methods: EPS was performed in 51 patients aged from 13 to 50 years
(mean 30±16) for a PS. Atrial stimulation was performed in control state (CS)
at a cycle length of 400ms and coupling was decereased until AP6RP or atrial
RP. Measurement was repeated after isoproterenol when AP-RP≥250ms in
CS. Measurement was performed by transesophageal route and then by intra-
cardiac route, with a delay not >3 months. 
Results: AP-RP’s were 267±50ms in CS, 233±49ms after isoproterenol at
transesophageal EPS, 309±72ms in CS, 280±64ms after isoproterenol at intra-
cardiac EPS (p<0.002). Among 31 patients with initially AP-RP ≥250ms at
transesophageal EPS, AP-RP was ≤220ms after isoproterenol in 12 patients.
All, but one had an AP-RP≥250ms in CS at intracardiac EPS; one patient with
AP-RP of 270ms at esophageal EPS had a value of 240ms at intracardiac EPS
in CS but value was 250ms after isoproterenol. Three patients with trans-
esophageal AP-RP in CS and after isoproterenol ≥280ms had lost their antero-
grade conduction. At transesophageal EPS, AP-RP was <250ms in 20 patients
of which only 8 had a short AP-RP at intracardiac EPS and 3 had a short AP-
RP after isoproterenol. There was no significant difference for the induction
of orthodromic tachycardia at transesophageal and intracardiac EPS (72%) and
there was a similar induction of atrial fibrillation at transesophageal EPS
(32%) and intracardiac EPS (28%).
Conclusions: A long AP refractory period measured at transesophageal
EPS excluded the presence of an AP with a short refractory period at intra-
cardiac study even after isoproterenol. There was an adrenergic factor during
transesophageal EPS and isoproterenol produced a significant shortening of
AP refractory periods in only 39% of patients with AP-RP ≥250ms. When
AP-RP is ≥280ms at transesophageal EPS, the loss of anterograde conduction
in AP can be expected in the following weeks (15%). 
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Long-term follow- up of AV conduction disturbances after slow
pathway ablation in patients with AV node reentrant tachycardia
Sarah Dorlet, Béatrice Brembilla-Perrot
CHU Nancy Brabois, Cardiologie, Vandoeuvre Les Nancy, France
AV block following radiofrequency (RF) ablation for the treatment of
atrioventricular nodal reentrant tachycardia (AVNRT) is a rare but well reco-
gnised complication of the procedure. The purpose of the study was to report
the long-term follow-up of patients a first d (AVB1), second d (AVB2), or
third d A V block (AVB3) occurred during ablation of AVNRT.
Methods: 930 patients, 615 females, aged from 12 to 92 years, mean age
52±18, had AVNRT. RF energy, 65°, 40 watts was delivered on the slow
pathway, until AVNRT was not induced. 
Results: 94 patients presented a transitory or permanent AVB1,2,3. In 8,
mean age 53±21.5 years, AVB was of vagal origin generally occurring at
femoral puncture (group I). In 26 patients, mean age 46±21, it was traumatic
and regressive occurring either in young patients with a normal conduction
system or in 3 patients with a left bundle branch block. In remaining 60
patients, AVB was directly related to the RF application; AVB was of first
degree in 22 patients aged 56±17 years; it was of 2nd or third degree AVB in
38 patients: in 2 patients AVB3 remained permanent and in all other patients
it was partially or totally regressive. After a follow-up of 2.1±2 years, pace-
maker implantation was implanted in 15 patients, 1 patient with traumatic
AVB3 aged 81 years, 5 patients with AVB3 during ablation, 2 with permanent
AVB3 (0.2%) and 3 with transitory AVB3 and 9 patients without AVB during
ablation. In these last patients, 2 had spontaneous long HV interval. Age of
these patients differed from age of patients with RF-related AVB (73±14 vs
56±17) (p< 0.04). 5 patients with transitory AVB3 remained symptomatic
with alternating slow junctional rhythm and sinus tachycardia. 
Conclusions: AVB remains frequent during AVNRT ablation (10%) but it
is frequently benign and not directly related to the RF application. Permanent
complete AVB is exceptional (0.2%). Patients with transitory complete AVB
remain at high risk of later events as conduction disturbances or sinus
tachycardia. Other AVB’s are age-related and probably without relation with
ablation. Permanent or transitory 1 degree AVB seems without clinical signi-
ficance. 
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Background: Little is known about predictors of high-degree atrioven-
tricular block (AVB) in patients without evidence of advanced His-Pur-
kinje conduction disturbances at electrophysiological study (EPS)
performed for unexplained syncope associated with bundle branch block
(BBB). 
Aims: Identify electrocardiographic predictors of high-degree AVB
during follow-up of these patients. Methods. In this multicenter cohort,
patients were included if they had: (1) unexplained syncope, (2) bundle
branch block (≥120ms), (3) no HPCD at EPS, i.e. baseline HV interval
<70ms, and absence of 2nd- or 3rd-degree AVB induced with atrial pacing
or ajmaline challenge. 
Results: Among the 150 studied patients (72±14 years, 62% male, mean
left ventricular ejection fraction 57±8%), index electrocardiograms showed
right BBB (70%; n=105), left BBB (2.7%; n=41), and nonspecific intraven-
tricular conduction disturbance (3%; n=4). A first-degree AVB was noted in
62 patients (44.3%). During a mean follow-up of 584±88 days, high-degree
AVB was documented in 25 patients (17%). The presence of a first-degree
AVB on the index electrocardiogram was associated with an increased risk
of subsequent high-degree AVB [72% vs. 35%; p<0.01]. Conversely, no
patients with isolated right BBB developed high-degree AVB after a normal
EPS. 
Conclusion: In patients with unexplained syncope associated with BBB,
16% of patients subsequently developed high-degree AVB despite no evi-
dence of advanced HPCD at EPS. This was more likely to occur in patients
with first-degree AVB at presentation. Conversely, this finding never occurred
in patients with isolated RBBB and normal PR interval. 
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Introduction: long QT and related ventricular arrhythmias may complicate
the evolution of Eating Disorders (ED) but duration of QT interval and pre-
valence of long QT in large series of ED patients has not been reported.
Methods: QT intervals were measured in 100 consecutive ED patients
(anorexia nervosa, bulimia nervosa or mixed) in lead II, V2 and V5 and
corrected using Bazett’s formula. 95 healthy subjects matched in age and
gender forms the control group. 
Results: mean age was 30±12 yo and 93% were females. Mean Body
Mass Index (BMI) was 16.9±3kg/m2. Heart rate was significantly lower in
patients with ED (64±14 bpm) compared to controls (78±15 bpm)
(p<0.0001).
QT were significantly longer in ED patients than in controls in leads II
(384±33 vs 366±32, p=0.0003), V2 (377±37 vs 367±35ms, p=0.04) and V5
(381±34 vs 365±30ms, p=0.0005). Corrected QT were significantly shorter in
patients with ED compared to controls in leads II (389±28 vs 412±28ms), V2
(383±27 vs 413±32ms) and V5 (387±26 vs 410±28ms) (p<0.0001 for each
comparison). None of the ED patients had a corrected QT >480 msec (max
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464ms). U wave was present in 16% of patients with ED and 4% in controls
(p=0.006).
BMI and heart rate were negatively correlated with QT in univariate ana-
lysis. After adjustment for BMI and heart rate, QT was significantly lower in
patients with ED in leads II, V2 and V5 (p<0.05). 
Corrected QT tended to be increased in ED patients receiving drugs known
to increase QT (p = 0.1). QT was negatively correlated to plasma magnesium
level (p = 0.01), to calcemia (p = 0.06) and to plasma albumin (p = 0.004).
QT was not associated to plasma potassium level. QT did not differ between
the different types of ED.
No patient did present with major event before inclusion or during follow-
up.
Conclusion: QT durations were found normal in patients with ED and
were even shorter than in controls when corrected or adjusted for heart rate.
QT was only related to BMI, calcium and magnesium plasma levels.
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Predictive value of the CHA2DS2-VASc score in atrial fibrillation
patients at high risk for stroke despite oral anticoagulation
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Introduction and objectives: The risk of stroke in atrial fibrillation is
heterogeneous and depends upon underlying clinical conditions included in
current risk stratification schemes. Recently, the CHA2DS2-VASc score has
been included in guidelines to be more inclusive of common stroke risk fac-
tors seen in everyday clinical practice, and useful in defining ‘‘truly low risk”
subjects. We aimed to assess the usefulness of CHA2DS2-VASc score to give
us an additional prognostic perspective for adverse events and mortality
among ‘‘real world” anticoagulated patients with atrial fibrillation who are
often elderly with many comorbidities.
Methods: Consecutive outpatients with permanent/paroxysmal non val-
vular atrial fibrillation with CHA2DS2-VASc > ou = a 2 and stabilized oral
anticoagulation (international normalized ratio 2.0-3.0) for at least the pre-
ceding 6 months were recruited. Patients with CHA2DS2-VASc > ou = a 2
were selected. Adverse cardiovascular events including stroke, acute coronary
syndrome, or heart failure; major bleeds; and mortality were recorded during
more than 2 -year-follow-up.
Results: Of 293 patients (93.5%) assessed, 167 were males, median age 76
(71-81) years. After a followup of 567 (432-665) days, 11.7% patients had
adverse cardiovascular events, 8.6%patients had major bleeds, 10.8% patients
died, and 24.6% major adverse events (composite endpoint).Increasing
CHA2DS2-VASc score by 1 point had a significant impact on the occurrence
of cardiovascular events (hazard ratio=1.27; 95% confidence interval, 1.13-
1.44; P<.001), mortality (hazard ratio=1.36; 95% confidence interval, 1.19-
1.54, P<.001); and major adverse events (hazard ratio=1.23; 95% confidence
interval, 1.13-1.34; P<.001). CHA2DS2-VASc score was not associated with
major bleeding episodes.
Conclusions: Among high risk atrial fibrillation patients on oral anticoa-
gulation, CHA2DS2-VASc successfully predicts cardiovascular events and
mortality, but not major bleeds.
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Background: It is well established that tonic-clonic seizure-like activity
can be part of a syncope yet many patients with these clinical features are mis-
diagnosed with seizures and often referred to epilepsy centers. Head-up tilt
test (HUT) is the gold standard for diagnosing vasovagal syncope, but it can
fail to provide clinical details that help distinguish convulsive syncope from
epileptic seizures. We aimed to evaluate the diagnostic yield of a combined
HUT and video-EEG monitoring strategy in patients with atypical episodes of
unexplained loss of consciousness (LOC).
Methods and results: A total of 87 patients (mean age 32±15 years, 71%
women) who underwent HUT with concomitant video-EEG between March
2007 and August 2013 were retrospectively analyzed. Events were classified
as vasovagal syncope, epilepsy or psychogenic. Median number of episodes of
LOC was 6 [range 1 – 30]. 45% of patients had prolonged LOC (>1 min),
75% had myoclonic jerks and 52% abnormal standard EEG. Antiepileptic
drugs (AEDs) were prescribed in 38 patients (43%). The majority of patients
(78/87) had undergone prior neurological and cardiac evaluation with routine
EEG, neuroimaging and/or Holter ECG, and HUT (n=30). HUT combined
with video-EEG was diagnostic in 67/87 (77%) of patients. Vasovagal syn-
cope was seen in 62/87 (71%), 31 of which had associated myoclonic jerks,
especially dose with severe bradycardia ≤40 bpm (n=26) or asystole (n=5).
Five patients (6%) experienced psychogenic non-epileptic events. Epilepsy
was diagnosed in only 8 patients (9%), and LOC remained unexplained in 12
(14%). AEDs were discontinued in non-epileptic patients as a result of the
testing.
Conclusions: Patients with convulsive syncope are often misdiagnosed and
treated with AEDs. Combined HUT and video-EEG monitoring is a useful
diagnostic test in patients with atypical episodes of unexplained LOC and can
avoid expensive non-diagnostic evaluations as well as ongoing treatment with
unnecessary AEDs. 
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Background: Implantable cardioverter-defibrillator (ICD) the best treat-
ment for secondary prevention in Brugada syndrome (BrS). However, asymp-
tomatic patients are still being implanted, regardless the high rate of device
complications. We compared the occurrence of complications in patients
implanted an ICD in several French centers. 
Method and results: Consecutive BrS Patients implanted an ICD for
primary or secondary prevention were studied. Per- and post-implantation
complications, and ICD programming controls were recorded. Patients or
relatives were also contacted by telephone to check last news (alive or
died). We studied 51 patients (mean age of 46.7±10.5 years, 10% of
female). Spontaneous type 1 ECG pattern was found in 40 (78%) of
patients and atrial fibrillation in 6 (12%). Prior to ICD implantation, No
symptom, Syncope, and aborted cardiac arrest were found in 19 (37%), 24
(47%), and 8 (16%) patients respectively. During a median follow-up
period of 76±41.7 months (at 1 to 192), appropriate ICD shocks occurred
in 11 (21.5%) patients of whom 90% had spontaneous coved type ECG,
40% had previous syncope and 60% already have experienced aborted
SCD. Seven (13.7%) patients had inappropriate shocks (IS), of whom 5
(71.4%) in asymptomatic, 28.6% in syncope group, and none in resusci-
tated group. Other Complications were reported in 10 (19.6%) patients.
Lead fracture, Lead dislodgement, pneumothorax, pocket infection, myo-
cardial perforation, and re-operation for any reason occurred in 4 (7.8%),
2 (3.9%), 1 (1.9%), 1 (1.9%), 1 (1.9%), and 9 (17.6%) respectively. The
incidence of IS is higher in asymptomatic vs symptomatic patients if we
consider the confidence interval of 90% (p=0.07) in this rare disease,
whereas other complications had similar rate occurrence. 
Conclusion: ICD was shown to be an effective therapy in symptomatic
patients, particularly in those with previous cardiac arrest. However, the high
rate of device complications, mainly inappropriate therapies recommends to
accurately assess the risk-benefit of cardioverter-defibrillator and avoid this
treatment in asymptomatic patients.
